## CHRW: C.H. Robinson Worldwide, Inc. - XLI: Industrials

### Executive Summary

No thesis match: MRS_10 0.4% below STRENGTH zone (3.0-6.0%); PEG 2.32 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($157.38)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. C.H. Robinson (CHRW) Gets Target Lift as Stifel Backs High-Quality Transport Names**
- Source: Insider Monkey | 20260103T000825 | Bullish | Relevance: 100%
- Stifel analyst J. Bruce Chan raised the price target for C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) to $184 from $155, maintaining a Buy rating. The firm expects transport stocks in 2026 to be influenced by supply rationalization and cost-focused initiatives, favoring high-quality names like CHRW that are expanding market share. C.H. Robinson's use of AI to streamline operations contributed to a profit beat in Q3 2025, demonstrating efficiency amid a challenging logistics sector.

**2. 11,425 Shares in C.H. Robinson Worldwide, Inc. $CHRW Bought by Calamos Advisors LLC**
- Source: MarketBeat | 20260102T085401 | Somewhat-Bullish | Relevance: 100%
- Calamos Advisors LLC has acquired a new stake of 11,425 shares in C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) during the third quarter, valued at approximately $1.513 million. Institutional investors and hedge funds now own about 93.15% of the company's stock, while corporate insiders recently sold a significant number of shares. Wall Street analysts maintain a "Moderate Buy" consensus rating for CHRW, with an average price target of $149.48, and the company recently increased its quarterly dividend to $0.63 per share.

**3. Hennessy Advisors Inc. Invests $44.46 Million in C.H. Robinson Worldwide, Inc. $CHRW**
- Source: MarketBeat | 20260101T115914 | Somewhat-Bullish | Relevance: 98%
- Hennessy Advisors Inc. acquired 335,800 shares of C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) in Q3, valued at approximately $44.46 million, making it their 8th largest holding. Despite some insider selling by Michael D. Castagnetto and Angela K. Freeman, the company reported strong Q3 EPS of $1.40, exceeding estimates, and increased its quarterly dividend to $0.63. Analysts maintain a "Moderate Buy" rating with an average target price near $149.48.

**4. 2025â€™s best-performing Minnesota public company stock is a biopharmaceutical firm with no revenue**
- Source: Star Tribune | 20260101T120514 | Somewhat-Bullish | Relevance: 83%
- Celcuity, a Plymouth-based clinical-stage biopharmaceutical firm, was the best-performing Minnesota public company stock in 2025, despite having no revenue. Its stock soared 663% due to positive clinical trial results for its cancer-fighting drug, gedatolisib, significantly increasing its market capitalization to $4.6 billion. Other top performers included Tactile Systems Technology, APi Group, C.H. Robinson Worldwide, and nVent Electric, driven by advancements in medical devices, AI, and data center technology.

**5. The Truth About Expeditors International (EXPD): Boring Name, Sneaky Power Move Stock?**
- Source: AD HOC NEWS | 20260102T000815 | Somewhat-Bullish | Relevance: 80%
- Expeditors International (EXPD) is a logistics giant that, despite its low-key profile, quietly manages global shipping and generates substantial cash flow. The article explores whether EXPD stock is a strategic investment for those seeking "boring but rich" plays in global trade, highlighting its asset-light model, strong financials, and stability compared to more volatile market options. It concludes that while EXPD may not be a viral sensation, it offers a solid and consistent option for long-term portfolio stabilization and diversification.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-24 | B of A Securiti | $182 | $167 | +9% |
| 2025-12-16 | Stifel | $184 | $155 | +19% |
| 2025-12-16 | Barclays | $200 | $145 | +38% |
| 2025-12-08 | Morgan Stanley | $85 | $77 | +10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-24 | B of A Securiti | main | Buy |
| 2025-12-16 | Stifel | main | Buy |
| 2025-12-16 | Barclays | up | Overweight |
| 2025-12-08 | Morgan Stanley | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 2 ($1.79M) |
| Sells | 2 ($0.38M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.0% (-3.0%)
- First Eagle Investme: 8.9% (-0.2%)
- Blackrock Inc.: 8.2% (-8.5%)
- Wellington Managemen: 6.1% (+198.6%)
- State Street Corpora: 5.8% (-7.4%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 4 raises (avg +19%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.32 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 34%). Analyst sentiment positive (4 raises, avg +19%). Insider buying signal ($1.8M), management confidence. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.3B |
| Beta | 0.91 |
| 52W Range | $84.68 - $167.90 |
| Short Interest | 6.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.32 |
| Forward P/E | 27.3 |
| Current P/E | 32.8 |
| YoY Growth | 20.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+0.5% over 5 days). Below STRENGTH zone by 2.6pp (needs >3.0% for momentum thesis). MRS_5 at 1.1% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.52), momentum weakening. OFD pattern: +MLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.42% (CS: 44) | Neutral |
| RSI_14 | 60.1 | Neutral |
| MACD Histogram | -0.52 | Bearish |
| vs SMA20 | 1.019x | Above |
| vs SMA50 | 1.067x | Above |
| vs SMA200 | 1.373x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $163.72
- **Stop Loss:** $157.38 (3.9% risk)
- **Target:** $170.06 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 227
- **Position Value:** $37,164.44
- **Portfolio %:** 37.16%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-01-28 (Est: $1.13)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.30 | $1.40 | +7.4% |
| 2025Q2 | $1.16 | $1.29 | +11.6% |
| 2025Q1 | $1.05 | $1.17 | +11.4% |
| 2024Q4 | $1.11 | $1.21 | +9.2% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*